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A B S T R A C T   
This article aims to envisage future perspectives of the lymphocyte transformation test (LTT). We describe the 
select innovative techniques, which can be integrated at different stages of the LTT to potentially improve the 
sensitivity, specificity, or practicability of the LTT. We first focus upon the cell sorting techniques comprising 
immunomagnetic cell separation and flow cytometry, which can be implemented prior and after the LTT 
culturing step to concentrate and quantify specific immune cell types. Further, we elaborate upon three 
important omics techniques such as transcriptomics, proteomics, and metabolomics, which can be integrated 
downstream of the LTT to analyze molecular changes in specific immune cells following drug induced activation 
and proliferation. We also develop visions, how state of the art techniques used in other scientific fields, can be 
transferred and applied in the context of in-vitro detection of drug allergy.   
1. Introduction 
The classical lymphocyte transformation test (LTT) offers valuable 
information on the diagnosis of hypersensitivity caused by the specific 
drug. However, the limited sensitivity and specificity of the LTT still 
warrants a joint approach of LTT combined with the classification of the 
clinical phenotype of the reaction, medical history, and complementary 
in-vivo testing i.e. skin tests and if necessary drug provocation test etc. for 
confirming the diagnosis (Brockow et al., 2015; Mayorga et al., 2017). 
Despite these drawbacks and associated technical difficulties, the LTT 
remains an acceptable choice in clinics for diagnosing delayed type drug 
allergy (Karami et al., 2016; Pichler & Tilch, 2004). However, it is not 
amenable to routine use in standard clinics due to involvement of 
radioactive isotopes in the classical LTT procedure (for more informa-
tion on the LTT, please see the separate article in this ‘Special Issue on 
the in-vitro detection of drug allergy’: “Lymphocyte transformation test: 
history and current approaches” by Sachs et al). Moreover, little has 
been changed in the basic LTT workflow (also referred to as LTT plat-
form) since its advent in the 1960s (Huber, Huber, & Braunsteiner, 
1966; Pichler & Tilch, 2004; Sarkany, 1967). Some amendments to the 
classical LTT have been introduced in the form of alternative readout 
parameters and methods. For instance, in the context of the classical 
LTT, the detection of activated T cells by flow cytometry or consequently 
produced cytokines analysis by ELISA are few of these modifications, 
which have already been implemented to detect drug-specific T cell 
activation in drug allergy (Martin et al., 2010; Sachs et al., 2002; 
Suthumchai et al., 2018). Additionally, researchers have modified the 
LTT to improve the drug specific activation through addition of IL2 
(Ikeda et al., 1998), IL-7/IL-15 (Porebski et al., 2013), professional an-
tigen presenting cells (Antunez et al., 2011; Lopez et al., 2009) or by 
removal of regulatory T cells (CD3+ CD25) (Srinoulprasert & Pichler, 
2014). Likewise, modification of the LTT by addition of anti-CD3/anti- 
CD28 monoclonal antibodies has been also tried, which led to 
increased sensitivity but simultaneously reduced specificity (Trautmann 
et al., 2014). In case of certain reactive drugs, hapten mediated immune 
activation is an important aspect of the immunopathology (Levine & 
Ovary, 1961; Naisbitt et al., 2002; Schnyder & Pichler, 2009). Therefore, 
addition of the reactive metabolite instead of the inert drug or the 
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addition of liver microsomes to generate the reactive metabolite has 
been also implemented (Sachs et al., 2001; Chipinda, Hettick, & Siegel, 
2011; Cho & Uetrecht, 2017; for additional information please see the 
separate article in this ‘Special Issue on the in-vitro detection of drug 
allergy’: “Lymphocyte transformation test: history and current ap-
proaches” by Sachs et al). Despite of all these proposed and implemented 
modifications, it appears that none of the aforementioned modifications 
has turned out to be a ‘game-changer’ and substantially improved 
sensitivity, specificity or applicability of the LTT. Thus, there is still a 
room and necessity for translating and integrating innovative methods 
to improve the in-vitro diagnostics of drug allergy via the LTT platform. 
Scientific and technical innovations in the last 20 years have trans-
formed the contemporary laboratory assays. It has led to increased 
sensitivity in analyzing subtle molecular changes in diverse biological 
processes. As the basic mechanism of drug allergy has its roots in the 
activation and expansion of drug-specific memory T cells, the detection 
of corresponding molecular changes in the immune cells could be 
promising for the in-vitro detection of drug allergy. 
The immunological basis of T cell mediated drug allergy is addressed 
in the separate manuscript “Lymphocyte transformation test: history 
and current approaches” by Sachs et al. in this “Special Issue on the vitro 
detection of drug allergy” (Fig. 1). Accordingly, multiple mechanisms 
such as haptenation, pharmacological interaction with immune re-
ceptors, or the altered peptide repertoire, have been also proposed to 
explain the observed T cell activation and formation of drug-specific 
memory T cells and are detailed elsewhere (Pichler, 2019; Weltzien 
et al., 1996; Yun et al., 2016). Although out-of-scope of this article, these 
or similar mechanisms may underlie the observed activation and pro-
liferation of the drug-specific memory T cells in the in-vitro LTT platform 
following co-incubation of the patient’s peripheral blood mononuclear 
cells (PBMCs) with the suspected drug. It is also important to note that 
the observed immune response in the in-vitro LTT platform may differ 
from the in-vivo situation due to limitations of formation or presentation 
of drug-protein conjugates in-vitro (Chipinda et al., 2011). However, 
although different types of drug allergies (i.e. type I – IV) may follow 
different mechanisms or exhibit different distal effector responses, they 
entail a basic mechanism of drug-mediated activation and proliferation 
of memory T cells during the allergic immune response (Cornejo-Garcia 
et al., 2007; Luque et al., 2008). These steps of the T cell activation and 
proliferation process are associated with changes in terms of cell 
numbers, transcribed genes, translated proteins, reprogrammed path-
ways, and thus by altered cellular metabolites2 levels. Therefore, the 
analysis of activated T cells or there in induced genes, proteins, and 
metabolites would not only extend our understanding of the mecha-
nisms of drug allergy but also identify potential biomarkers for moni-
toring drug induced immune system activation in drug allergy. In the 
next section, we will look at the future perspectives offered by selected 
innovative technologies to analyze cellular and molecular changes in the 
drug allergic reactions. 
2. Cell isolation and sorting: immunomagnetic cell separation 
and flow cytometry 
The classical LTT is performed using PBMCs which comprises mainly 
lymphocytes (B, T, and Natural killer cells), and monocytes. Upon 
culprit drug incubation, memory T cell activation results in cell prolif-
eration and differentiation. However, the final classical LTT read-out 
parameter (stimulation index) does not differentiate exactly which 
cells are activated and proliferating. This adds uncertainty to the clas-
sical LTT read-out parameter of ‘proliferation’ because, as stated above, 
PBMCs are not a homogeneous mixture of cells and may contain cells 
which are already proliferating or may proliferate irrespective of a drug- 
specific activation. On another aspect, the number of drug-specific T 
cells are miniscule compared to the whole PBMCs population (Kalish 
et al., 1994; Beeler et al., 2006). Thus, even upon proliferation, the net 
number of the drug-specific T cells will still be low and corresponding 
cellular changes will be difficult to detect in the background of the whole 
T cell population. This may dilute any drug-specific response in the LTT 
‘proliferation’ read-out and result in low sensitivity of the overall 
downstream differential gene, protein, or metabolite analysis. 
The isolation and concentration of specific immune cells from PBMCs 
or blood using immunomagnetic cell separation technique is promising 
in the LTT platform, as they could increase the sensitivity and specificity 
of the drug specific T cell proliferation analysis by minimizing unnec-
essary cellular ‘background noise’. The strategy of immunomagnetic cell 
separation could be applied to concentrate specific T cells (either naïve 
or memory T helper (Th) or cytotoxic T (Tc) cells) or specific antigen 
presenting cell (APC) population via positive or preferably negative se-
lection (Horgan, Shaw, & Boirivant, 2009; Sutermaster & Darling, 
2019). Here, negative selection is preferable to positive selection as it 
avoids any interaction with the surface markers of the desired T cells or 
APCs, thus by reducing the chance for unwanted unspecific activation of 
the desired cells. The use of these isolated specific cell types for the LTT 
platform could reduce the interference or ‘background noise’ from the 
other cell types. Moreover, as PBMCs also contain diverse T cell types, 
including regulatory T cells (Treg) which suppress T cell activation, the 
removal of such cell types from the PBMC cultures may also likely 
reduce the suppression of the immune response (Srinoulprasert & 
Pichler, 2014). Another interesting approach, to reduce the suppression 
of the immune response may be through the addition of anti-PD-1/anti- 
PD-L1 (Rosskopf et al., 2018) or anti-CTLA4 antibodies (Hellings et al., 
2002) during LTT culturing step, as these antibodies have shown 
promise in cancer immunotherapy and are also involved in modulating 
allergic reaction (Seidel, Otsuka, & Kabashima, 2018). On the basis of 
the T cell type (Th or Tc) or APCs, which is specifically isolated and used 
in the LTT, it could help in determining the responsive T cell type for the 
observed drug allergic reaction provided that the in-vitro situation re-
flects the mechanisms taking place in-vivo. For instance, Bechara et al. 
(2019) have used antibody coupled magnetic microbeads to isolate 
naive Tc and Th cells to characterize Nickel hypersensitivity. Similarly, 
Antunez et al. (2011) provides evidence for recognition of iodixanol by 
dendritic cells to increase the cellular response in delayed allergic re-
actions. In our opinion, the isolation of specific T cell types and APCs 
using the immunomagnetic beads could easily be integrated prior to the 
drug incubation step in the classical LTT platform and thus, could in-
crease the sensitivity and specificity of the LTT. 
In contrast to an immunomagnetic cell separation approach where a 
selected cell type is isolated as a population, individual T cells can be 
counted and analyzed using flow cytometry as a read-out parameter 
(Martin et al., 2010). Additionally, it is known that various surface 
markers are upregulated in T cells upon activation such as, CD69 for 
early activation stage, CD25 for late activation stage, and HLA-DR for 
even later activation stage (Beeler et al., 2008; Caruso et al., 1997). 
These markers could be used to characterize the drug specific activated 
T cells as readout parameter or to isolate them using flow cytometry for 
downstream analysis. This was demonstrated by Piroird et al. (2015) 
and Galbiati et al. (2016) where flow cytometry analysis has been 
employed for measuring the expression of CD86 to assess the activation 
of dendritic cells upon the chemical sensitization. Furthermore, the 
importance of flow cytometry for downstream omics analysis is 
demonstrated in a downstream single cell transcriptomics study, which 
revealed JAK–STAT signaling pathway as a potential target in a therapy- 
refractory drug-induced hypersensitivity syndrome/drug reaction with 
eosinophilia and systemic symptoms (DiHS/DRESS) (Kim et al., 2020). 
As illustrated by these examples, the quantification of the activated cell 
type frequency as well as isolation of the activated cells would be 
possible to monitor cellular changes at a single cell or cell population 
2 The term ‘metabolomics or metabolites’ refers to the cellular metabolites 
which constitute normal cellular physiology. It does not refer to drug and/or its 
in-vivo transformed drug products. 
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level. Therefore, we think that flow cytometry, when integrated in the 
read-out phase of the LTT platform, could be readily used to analyze the 
activated T cells individually or to further isolate them for the down-
stream analysis. 
Both immunomagnetic cell separation and flow cytometry tech-
niques will be particularly helpful in isolating the specific T cell type 
prior and after the LTT culturing step, respectively. However, they can 
also be implemented singly, in tandem or in reverse order in a LTT 
platform. Both techniques have their limitations and the selection of cell 
sorting technique depends upon the processing time, cell yields, and 
viability of resulting cells (Sutermaster & Darling, 2019). In a nutshell, 
we believe that the approach of immune cells (T cell and/or APCs) 
isolation by immunomagnetic beads and subsequent co-incubation with 
drug may increase sensitivity of the LTT. Additionally, flow cytometry 
analysis of T cells after the LTT will be helpful to quantitatively analyze 
the specific activated T cells and their corresponding proliferation. This 
will increase the confidence in the LTT proliferation read-out. Moreover, 
the collection of immune cells following the aforementioned combined 
approach will be highly specific to drug allergic reaction and further 
ease the downstream cellular analysis by various omics techniques. 
3. Omics 
Modern day omics methods generate quantitative information on an 
entire complement of expressed genes (transcriptomics), proteins (pro-
teomics), or metabolites (metabolomics). The integration of this infor-
mation in a systems biology approach is a promising way to enhance our 
understanding of drug allergy. Here, we discuss these three important 
omics technologies, what potential they carry if applied in the context of 
in-vitro drug allergy detection, and how they could be implemented in 
the context of the classical LTT platform (Fig. 1), thereby also furthering 
our understanding of the molecular changes upon T cell activation and 
proliferation. Moreover, if they are combined with the cell sorting 
techniques to focus on selected target cells as described before, the 
sensitivity and specificity of the downstream cellular analysis could even 
further be increased. 
4. Transcriptomics 
As per the central dogma of biology, gene expression directly or 
indirectly governs all the basic biological processes. Analyzing gene 
expression is, thus, a powerful and commonly used tool in molecular 
biology to elucidate basic biological processes, diseases, and specific 
pathologies. The gene expression analysis, also known as tran-
scriptomics, delivers quantitative information on the expression of sin-
gle or multiple genes in the cells. It is studied using various techniques 
ranging from northern blot, reverse transcriptase- real time-PCR (RT- 
qPCR) for a small number of transcripts, to DNA microarrays, RNA-seq 
Fig. 1. Implementation of novel techniques at different stages of the T activation and proliferation process in a classical LTT platform. Firstly, immunomagnetic cell 
separation can be applied prior to the LTT to concentrate the specific immune cells. Later, flow cytometry can be applied after the LTT platform to analyze the 
individual activated immune cells or to isolate them for the downstream omics analysis. Isolated cells can then be analyzed using transcriptomics, mass spectrometry 
(MS) based proteomics, and MS based metabolomics techniques to unravel differential molecular changes in drug allergic reactions. [APC: Antigen presenting cells, 
Th: T helper (CD4+) cells, Tc: cytotoxic T (CD8+) cells, Treg: regulatory T cells] 
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etc. for multiple transcripts in a high throughput manner (Lennon, 2000; 
Wang, Gerstein, & Snyder, 2009). These high throughput techniques of 
global gene expression analysis are now well established and able to 
deliver detailed information on absolute and relative gene expression 
levels, gene isoforms, translocation events, and nucleotide variations 
(Wang et al., 2009). Among the gene expression analysis techniques, 
RNA-seq by next generation sequencing (NGS) is promising as it can 
deliver quantitative information on multiple RNA transcripts without 
prior gene sequence knowledge needed and has also less background 
noise and greater dynamic range (Wang et al., 2009). Additionally, 
single cell RNA expression analysis technique which detects RNA mol-
ecules directly from the cell extract using fluorescence based comple-
mentary probes might also be of interest (Geiss et al., 2008; Tsang et al., 
2017), as it can be used to perform relative quantification or analyze 
gene expression from a single cell (Subkhankulova & Kelsh, 2019). With 
these respective features, both RNA-seq or single cell RNA expression 
analysis technique would be well suited for differential gene expression 
analysis of T cells after a LTT. 
The immune response involving drug induced T cell activation and 
subsequent proliferation is invariably controlled by expression of un-
derlying genes. This is evident in the T cell transcriptomics analysis 
showing a significant increase in LAT1 expression, which is involved in T 
cell metabolism, and superoxide dismutase 2, interferon-induced 
transmembrane genes 1 and 2 which are involved in T cell activation 
and effector functions upon abacavir patch test (Redwood et al., 2019). 
Upon activation, several co-stimulatory molecules such as ICOS 
(CD278), 4-1BB (CD137), OX40 (CD134) (Watts, 2005), and diverse 
cytokines are known to be produced by T cells or APCs (Chen et al., 
2018). In line with that, high level of in-vivo ICOS expression was 
observed in Treg cells upon contact hypersensitivity to 2,4-dinitro-fluo-
robenzene (Vocanson et al., 2010). Similarly, Redwood et al. (2019) 
showed the significant upregulation of the IFN-γ and IFN-α response 
pathways in T cells from abacavir-exposed skin. Expression of important 
stimulatory cytokines such as IL-4, IFN- γ is also significantly upregu-
lated in immediate or delayed type allergic response, respectively 
(Cornejo-Garcia et al., 2007). Not only mRNA but also certain microRNA 
(miRNA) populations have altered expression in drug specific Th cells 
from hypersensitive patients (Monroy-Arreola et al., 2018). Particularly, 
miR-155 was shown to be up-regulated in PBMCs from all hypersensitive 
patients 24 h after drug treatment, hinting it to be an early diagnostic 
biomarker of drug hypersensitivity reactions (Monroy-Arreola et al., 
2018). Moreover, various drugs are known to induce drug specific 
metabolism and corresponding gene expression pattern (Burczynski 
et al., 2000). These transcription fingerprints could be used to identify 
the culprit drug in a drug allergic reaction and the mechanism of im-
mune activation by the specific drug type. Similarly, drugs which could 
inhibit the T cell proliferation could also be identified through their 
effect on signaling pathways as illustrated in the transcriptomics anal-
ysis by Kim et al. (2020) that tofacitinib suppressed T cell proliferation 
in-vitro in DiHS/DRESS through suppressing JAK–STAT signaling 
pathway (Kim et al., 2020). At the later time points of the LTT, T cell 
activation culminates into subsequent proliferation through rapid cell 
divisions (Glinos et al., 2018). The gene expression analysis performed 
at extended time points should also be able to capture enhanced 
expression of cell division genes. In overall, transcriptomics analysis 
using RNA-seq technique for differential gene expression could be able 
to reveal early and late transcriptional changes in drug allergy and 
identify associated pathways. 
5. Proteomics 
The immune response is directly influenced by enzymes and immu-
nological proteins. Therefore, changes in drug allergic reactions are also 
reflected in the protein composition of the immune cells (Berge et al., 
2019). Although gene expression is a precursor to the protein synthesis, 
it does not necessarily provide the quantitative measure of 
corresponding protein levels in cells (Gry et al., 2009; Liu, Beyer, & 
Aebersold, 2016), as post-transcriptional modifications affects the 
mRNA half-life and translational efficiency. Filling this gap necessitates 
the qualitative and quantitative proteomics analysis to determine the 
extent of immune response. 
In various fields of science, several methods such as SDS-PAGE, 
native PAGE, ELISA immunoassays are implemented to analyze few 
proteins in cells at a time. However, global protein profiling can be 
possible using high throughput proteomics methods such protein chips, 
protein microarrays, or mass spectrometry based proteomics (Chan-
dramouli & Qian, 2009). Among them, mass spectrometry based pro-
teomics (MS-proteomics) has been a versatile and commonly used 
technique for the analysis of a complex protein sample (Chandramouli & 
Qian, 2009). In MS proteomics, whole proteins or their peptides are 
ionized and analyzed using mass spectrometer to identify the present 
proteins. Alongside the protein identification, relative or absolute 
quantification can be achieved using multiple chemical or metabolic 
stable isotope labeling methods as reviewed by Lindemann et al. (2017). 
Moreover, employing the phosphatase inhibitors during the protein 
extraction procedure, post-translational phosphorylation and dephos-
phorylation events can also be studied at the protein levels (Phospho-
proteomics) (Mayya & Han, 2009). 
Early signaling events in T cell activation involves phosphorylation 
or dephosphorylation at the protein level (Graves & Krebs, 1999; Hwang 
et al., 2020). T cell antigen receptor (TCR) proximal signaling involves 
phosphorylation of adapter protein LAT, through Lck mediated activa-
tion of zeta-chain-associated protein tyrosine kinase 70 (ZAP-70) 
(Smith-Garvin, Koretzky, & Jordan, 2009). TCR-induced production of 
diacylglycerol (DAG) also results in the membrane recruitment of 
RasGRP, where it is phosphorylated and activated by protein kinase C 
(PKC) (Smith-Garvin et al., 2009). These and other early signaling 
events could be captured in a phosphoproteomics analysis of T cells after 
the short period of drug incubation, as demonstrated by Tan et al. (2017) 
who identified hundreds of phosphorylation events, mainly among 
cytoplasmic and cytoskeletal proteins, induced immediately after TCR 
stimulation. Activated T cells are also known to co-express OX40 
(CD134) and IL2RA (CD25) which can be used as a marker for drug- 
specific activation of CD4+ T cells (Zaunders et al., 2009) as demon-
strated in allergic patients who experienced non-immediate reactions to 
imatinib (Klaewsongkram et al., 2016). Other T cell activation markers 
such as CD69 (Beeler et al., 2008), PD-1, TNFSF11, and IL-2 (Lochmatter 
et al., 2009) are also known to be involved in drug allergic response and 
are gradually upregulated after T cell activation (Tan et al., 2017). The 
pathway analysis of these proteins shows induction of protein trans-
lation, cell metabolism, cell cycle, protein degradation, and cytokine 
signaling (Tan et al., 2017). As the same proteins and pathways are also 
likely to be involved in drug-mediated T cell activation, they could bear 
the potential to be possible read-out parameters for the in-vitro detection 
of drug allergy. 
Many cytokines such as IFN- γ and IL-2, IL-5 etc. are expressed and 
released extracellularly during the T cell mediated delayed type drug 
hypersensitivity (Chen et al., 2018; Lochmatter et al., 2009). Accord-
ingly, their in-vitro detection in the LTT platform by ELISA has already 
been added as an additional read-out parameter to the current LTT 
platform (Lochmatter et al., 2009; Sachs et al., 2002). Interleukin-15 is 
also proposed as a marker for early diagnosis and prognosis monitoring 
as its levels are associated with severity and mortality in Stevens- 
Johnson Syndrome/Toxic Epidermal Necrolysis (Su et al., 2017). 
Monitoring of cytokines by MS proteomics methods is, however, chal-
lenging because of their very low concentrations (Kleiner et al., 2013), 
which makes it hard to be detected by even sensitive MS methods (Khan, 
2012; Mendoza-Porras et al., 2020). Thus, before the LTT supernatant 
can be analyzed by MS, these low abundant target proteins need to be 
enriched using immunoaffinity (immunobeads or antibodies) (Bandow, 
2010; Millioni et al., 2011). However, care must be taken during the 
enrichment steps as they can lead to a big loss of low-abundant protein 
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adhered to the carrier or other non-specific proteins (Ahn & Khan, 2014; 
Granger et al., 2005). These enrichment steps need to be experimentally 
tailored to the cytokines analysis in cell media or supernatant (secre-
tome) of the LTT platform. However, if feasible, LTT supernatant anal-
ysis will provide the complement of cytokines released during T cell 
activation, which could widen the spectrum of cytokines as a readout 
parameter for the LTT. At later time-points of the LTT platform, T cell 
activation results into T cell proliferation. This will be reflected in 
enhanced levels of DNA transcription, energy metabolism, and cell di-
vision proteins, as shown in integrative proteomics study which iden-
tified significant protein enrichment in protein translation (ribosome), 
cell metabolism, cell cycle, and protein degradation pathways (Tan 
et al., 2017). 
In overall, T cell activation and proliferation will be evident at 
various levels in phosphoproteome, secretome, and global proteome 
analysis by MS. However, as many of these changes are very subtle and 
instantaneous, the appropriate time point selection and snap harvesting 
of samples for proteomics and phosphoproteomics analysis will likely 
play a crucial role. Although out of scope of this article, careful sample 
preparation, sensitive MS data acquisition, and choice of appropriate 
data analysis workflows is also critical in the proteomics analysis. 
Moreover, as the LTT platform involves in-vitro culturing of PBMCs, MS 
quantification strategy called ‘stable isotope labeling by amino acids in 
cell culture’ (SILAC) (Ong et al., 2002), which involves culturing of 
target cells in media containing isotope labeled amino acids, might be of 
interest and amenable in the context of the LTT platform. SILAC uses 
isotopically labeled amino acids in the growth medium. The cultured T 
cells in the LTT platform would incorporate these isotopically labeled 
amino acids into proteins during the T cell proliferation. As MS can 
distinguish on the basis of mass, multiple samples labeled with different 
isotopes can be pooled and analyzed together. Thus, SILAC strategy will 
allow for precise and high confidence relative quantification between 
control and treatment sample in the LTT platform, as samples can be 
combined and processed together from the very first step of the exper-
imental MS-proteomics workflow (Chen et al., 2015). The successful 
implementation of quantitative MS-proteomics in the LTT platform 
could potentially extend our understanding of the proteins involved in 
the T cell activation and proliferation process, and identify inducible 
proteins which could serve as potential read-out parameters or markers 
for the in-vitro detection of drug allergy. 
6. Metabolomics 
Differential gene and protein expression ultimately affect the intra/ 
extra-cellular metabolites levels, which determines the actual pheno-
type of cells. Metabolomics delivers identification and quantification of 
the various metabolites at a given time point. It is performed in targeted 
mode where only specific metabolites of interest are analyzed, or in an 
untargeted mode where all detectable metabolites come under revision 
(Patti, Yanes, & Siuzdak, 2012). Among various analytical techniques, 
MS based metabolomics is a commonly employed method, owing to its 
versatility to analyze several chemically different analytes, high sensi-
tivity, and dynamic range (Tsugawa et al., 2014). Here, we explore the 
scope of MS-metabolomics approach to analyze metabolite changes in 
the immune cells in the LTT platform. 
PBMCs used in a LTT platform are comprised of multiple types of T 
cells and their effector counterparts (Fig. 1). Different T cells types may 
have their unique metabolic profiles depending upon the key metabolic 
regulator (Maclver, Michalek, & Rathmell, 2013; Michalek et al., 2011). 
Thus, depending upon the kind of drug and the involved key metabolic 
regulator, different T cells types may respond metabolically very 
different upon T cell activation and proliferation (Maclver et al., 2013). 
This forms the basis for our assumption that the metabolic profile of 
sensitized T cells from allergic individuals will be different from the 
control T cells (Maclver et al., 2013) and these metabolic differences will 
be even more amplified upon T cell activation in a positive LTT. The 
literature on the T cell metabolic changes in drug allergy is sparse but 
the parallels can be drawn from other metabolic studies involving the T 
cell activation and proliferation. 
It is known that T cell activation results in a rewiring of the cellular 
metabolism to support consequent rapid growth and cell division. 
Accordingly, metabolomics studies have already shown that the immune 
response is associated with strong metabolic changes particularly in the 
energy metabolism of T cells (Maclver et al., 2013). T cell activation and 
costimulation promotes the synthesis of the macromolecules to enable 
the immune response. To fulfil the demand of precursors for macro-
molecule synthesis and upregulated anabolic pathways, T cells up- 
regulate energy uptake and energy metabolism in terms of glycolysis, 
glutaminolysis, oxidative phosphorylation, and mitochondrial biogen-
esis (Chapman, Boothby, & Chi, 2019). Upregulated glucose, glutamine, 
and arginine utilization by T cells as well as upregulated levels of in-
termediates from these pathways indicate towards T cell metabolic 
rewiring. Increased glycolysis in activated T cells is similar to the War-
burg effect seen in tumor cells, resulting in pyruvate accumulation or 
lactate release from the cells (Hiemer et al., 2019). Likewise, increased 
lactate levels were shown to be directly correlated with the asthma 
severity in patients (Ostroukhova et al., 2012). von Meyenn, Bertschi, 
and Schlapbach (2019) has also reviewed recent insights into T cell 
metabolism and discussed its importance in T cell-mediated skin dis-
eases such as psoriasis and allergic contact dermatitis (von Meyenn 
et al., 2019). However, these points need to be validated in the wider 
context of drug allergy. 
Not only intracellular metabolism but also nutrient supply in the 
form of glucose, amino acids and fatty acids, is known to influence the T 
cell activation and proliferation response (Fox, Hammerman, & 
Thompson, 2005; Maclver et al., 2013). Particularly, external glucose 
uptake and utilization plays a critical role in the T cell proliferation 
response (Fox et al., 2005; Maclver et al., 2013; Michalek et al., 2011). 
Glycolysis is a required part of the metabolic response of T cells to 
proliferative signals and T cells do not proliferate in glucose deficient 
media, even in the presence of alternative energy sources such as the 
amino acid glutamine (Greiner, Guppy, & Brand, 1994). Therefore, 
glucose concentration in the LTT media might be an important consid-
eration for the LTT performance. Keeping that in mind, the rapid utili-
zation and resulting depletion of glucose or increase of lactate levels in 
the media composition of the LTT platform may also form interesting 
indicators for the T cell proliferation response and thereby the LTT 
performance. 
The IgE mediated immediate (type I) drug allergies exhibit an im-
mediate response through the release of inflammatory mediators 
(Schnyder & Pichler, 2009). This immediate response results from the 
crosslinking of drug specific IgE antibodies bound to the FcεRI receptors 
on the surface of mast cells and basophils, which then release inflam-
matory mediators such as histamine, heparin, tryptase etc. (He et al., 
2013; Stone, Prussin, & Metcalfe, 2010). The classical LTT platform, 
which excludes mast cells (which mainly reside in connective tissues) 
and basophils (which are circulating in the blood) in the assay, there-
fore, would not be able to manifest the release of the mentioned in-
flammatory mediators. However, there are many other in-vitro tests 
available, which focus on the detection of drug specific IgE or subse-
quent mechanisms but they are subject to separate articles in this 
“Special Issue on the in vitro detection of drug allergy” (please see: 
“Basophil and mast cell activation tests by flow cytometry in immediate 
drug hypersensitivity: diagnosis and beyond” by Elst et al., and 
“Detection of drug-specific immunoglobulin E (IgE) and measurement of 
biomarkers for acute drug hypersensitivity reactions” by Brockow et al., 
2015). 
In case of hapten or pro-hapten drugs, the extent of haptenation may 
influence the observed immune response. For hapten drugs, the avail-
ability of the binding-proteins is important (Cho & Uetrecht, 2017; 
Sanchez-Gomez et al., 2017; Yvon, Anglade, & Wal, 1990). For pro- 
hapten drugs, the biotransformation of pro-hapten drugs 
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(bioactivation) to reactive metabolites, which then bind to proteins to 
induce the T cell mediated immune response, is important (Chipinda 
et al., 2011; Cho & Uetrecht, 2017; Naisbitt et al., 2002; Sanderson, 
Naisbitt, & Kevin Park, 2006). Thus, determining the extent of 
biotransformation and haptenation is an important but elusive aspect in 
in-vitro assays. In the proposed LTT platform, downstream metabolomics 
analysis could be used to identify the drug-metabolites levels and thus 
the extent of drug bioactivation, whereas proteomics could be per-
formed to find out specific drug-protein conjugates (Ariza et al., 2012), 
which induce the immune response. 
Finally, as metabolites are generally the final effector or effected 
molecules, the metabolites levels in a whole PBMC population or 
selected T cell types in the final phase of the LTT platform, or released 
inflammatory mediators may directly correspond to the strength of the 
allergic immune response. As a vision, we think that the inclusion of 
metabolic profiling in a LTT platform would not only unravel the 
induced metabolites and metabolic pathways but also identify metabo-
lite markers for the variable proliferation response observed in a LTT in 
the context of drug allergy. 
7. Conclusion 
From the plethora of molecular biology techniques, which could be 
used to analyze T cell activation in drug allergy, we have illustrated 
selected techniques, which, from our perspective, are most promising 
and easily integrable to monitor molecular changes in T cell activation 
upstream or downstream of the classical LTT platform. The multiplex 
and high-throughput nature of these techniques could deliver informa-
tion on several interdependent parameters (cell type counts, expressed 
genes, proteins, metabolites) which could provide a basis for the dis-
covery of new read-out parameters for the T cell activation in drug 
allergic reactions in-vitro. However, due to the complex nature of im-
mune response in drug allergic reactions, it may not be the single gene or 
protein or metabolite but rather combinations of thereof which could 
form the effective panel of markers to detect a drug-specific sensitization 
in-vitro. It is important to reiterate at this point that these molecular 
changes are dependent upon the state of the T cell in an immune cascade 
and thus are very rapid, transitory and time-bound. Thus, choosing the 
right time point for the sample collection is of paramount importance. 
Additionally, due to low amount of cells or sample in terms of RNA, 
proteins or metabolites and associated inherent biological variability, 
micro-sample preparation methods and experimental consistency will 
be of extremely importance while dealing with these samples. With 
appropriate time-point selection and processing, these approaches could 
be able to unravel the key molecular changes and complement the 
current LTT platform with new read-out parameters for the in-vitro 
detection of drug-specific T cell sensitization, which in combination 
with other diagnostic findings allows for the conclusion of a drug 
allergy. 
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